A healthtech product evaluation is a structured review of whether a digital health product works clinically, fits the workflow it enters, protects patient data and can be sold and supported at scale. Done well, it tells a founder what to fix before a health system asks, and tells an investor which risks are priced into a deal. The strongest evaluations are led by someone who has practiced medicine and built a company, because the questions that decide adoption are clinical and commercial at once.
This guide is written for healthtech and healthcare SaaS founders, and for the venture capital and private equity teams backing them. It sets out the domains to assess, the evidence each one needs, how AI changes the work, and how to turn findings into decisions.
TL;DR
- A product evaluation is broader than a formal health technology assessment: it covers evidence, usability, privacy and security, workflow integration, cost and equity in one view.
- Match the evidence to risk. A scheduling tool needs usability proof. A diagnostic that guides treatment needs accuracy against a reference standard and, at the high end, outcome data.
- Health systems buy on clinician-vetted evidence and workflow fit. Developers tend to lead with clinical claims and ROI. Evaluate against the buyer's list.
- AI-enabled products need independent test data, subgroup analysis and a plan for monitoring performance after launch.
- Rank findings by how much they threaten a sale or a deployment, then fix in that order.
Table of Contents
- What a healthtech product evaluation is, and how it differs from an HTA
- The domains every evaluation should cover
- Clinical evidence: how much is enough
- Usability and workflow fit
- Privacy and security
- Implementation readiness and commercial viability
- Evaluating AI-enabled products
- From findings to decisions
- Where a physician-led evaluation fits
- Our perspective
- FAQ
- Sources
What a healthtech product evaluation is, and how it differs from an HTA
Two terms get mixed up. Health technology assessment (HTA) is the formal, multidisciplinary process payers and public bodies use. A 2026 scoping review describes it as a systematic process across a technology's life cycle that weighs clinical effectiveness, safety, costs and wider social, ethical and organizational impacts. The same review finds that generic HTA frameworks fall short for digital health because of rapid development, unusual technical features and integration complexity.
A product evaluation is the working version of that idea, built for the decisions a company actually faces: Is this ready for a pilot? Is this worth funding? Is this safe to roll out across our clinics? It borrows the rigor of HTA and adds the commercial and operational questions HTA leaves out.
The need for a tailored approach is real. A 2026 European paper notes that digital health technologies evolve continuously, often incorporate AI, have broad intended uses and can shift purpose after deployment, which is why dedicated frameworks now exist in Spain, Finland and England. In the United States, the best-known public example is the ICER and Peterson Health Technology Institute framework for digital health value assessment.
The domains every evaluation should cover
A 2025 mixed-methods study built an evaluation framework for digital health software from a needs assessment of 173 subject-matter experts, a review of 1,053 papers, an analysis of 160 existing frameworks and standards, and 58 validation interviews. Its top three quality domains were evidence, usability, and privacy and security, with equity and inclusion running through all of them.
For a founder or an investor, a practical evaluation adds two more: implementation readiness and commercial viability. Here is how the six fit together.
| Domain | Core question | Typical evidence |
|---|---|---|
| Clinical evidence | Does it do what it claims, safely? | Validation studies, outcome data, clinician review |
| Usability | Can the intended users complete critical tasks? | Task-based testing, validated usability scales |
| Privacy and security | Can a health system trust it with patient data? | HIPAA program, risk assessment, third-party audit |
| Workflow and integration | Does it fit how care is delivered? | EHR integration, pilot feedback, support model |
| Commercial viability | Who pays, and does the math hold? | Cost, reimbursement path, ROI, retention |
| Equity and inclusion | Does it work across the real patient population? | Diverse validation cohorts, subgroup results |
Clinical evidence: how much is enough
The most common mistake is treating evidence as a single bar. It is a sliding scale tied to risk.
The ICER-PHTI framework tiers digital health products by risk. Tier 2 covers active monitoring and diagnostic or decision-guiding software. For lower-risk diagnostics, the minimum is accuracy and precision measured against a well-established reference standard, and better evidence is external validation in an independent population. High-risk diagnostics, such as cancer diagnosis, may need a randomized trial showing improved patient outcomes. Where outcome measurement is not feasible, the framework looks to studies of changes in clinician diagnostic impressions or behavior.
For software that meets the FDA definition of a medical device, the International Medical Device Regulators Forum sets out three pillars. Its guidance says evidence of valid clinical association, analytical validation and clinical validation is essential to establishing value, and the degree of evidence depends on how mature the underlying clinical evidence is. It also notes that real-world performance data after launch, including safety data, new publications and end-user feedback, can support changes to functionality and intended use.
A researcher-led review describes digital product evaluation as having technical validation, clinical validation, usability validation and cost assessment, and calls it an ethical imperative to evaluate tools prospectively in diverse populations. Put plainly:
- Technical validation: Is the output accurate and precise?
- Clinical validation: Does it improve quality measures or outcomes, or give clinicians useful diagnostic or management information?
- Population coverage: Was it tested on people who look like the patients it will serve?
A worked example
Imagine a remote-monitoring product that flags early deterioration in heart failure patients. It informs treatment decisions, so it sits in the higher-risk tier. A credible evidence plan would show agreement with a clinical reference standard, then external validation at a second site with a different patient mix, then a prospective study of whether clinicians act differently and whether outcomes improve. If the company has only the first step, the evaluation should say so plainly and set out what the next study must show. That is a roadmap, not a verdict.

A clinical strategy built early saves months here. Our guide to clinical strategy for digital health companies covers how to sequence evidence with the product roadmap.
Usability and workflow fit
A product can be accurate and still fail because clinicians will not use it. The ICER-PHTI authors define usability as the ease and satisfaction with which end users complete the product's intended purpose. They point to the System Usability Scale as an established, validated instrument. They recommend that developers use the same measures earlier products used, so results can be compared indirectly, and that they document end-user engagement in design. The authors also explain that user experience drives consistent use, which is why it counts as evidence, even though the field has not settled on one best measurement approach.
For a startup, this translates into three habits:
- Test the critical tasks, not the whole interface. Start with the actions where an error would harm a patient or stall a clinic day. We cover the approach in healthcare software usability testing.
- Test with the real mix of users: physicians, nurses, front-desk staff, administrators and, where relevant, patients.
- Measure in the setting of use, whether clinic, hospital or home.
Workflow fit is the sibling question. The 2025 framework study found that adopters prioritized clinician-vetted evidence and workflow integration, while developers prioritized evidence for clinical claims and ROI. That gap explains many stalled pilots: the company pitches its strongest slide, and the buyer asks about something else.
Integration is the hard part of workflow. Researchers describing digital tool deployments in large health systems note that tools need the right data stream at the right interval and must be embedded in the health system's information ecosystem, increasingly through standards-based APIs such as FHIR (a common standard for exchanging health data). If your evaluation finds integration is slow, our piece on a workflow-first EHR integration strategy shows where the time usually goes.
Privacy and security
Security questions decide more enterprise deals than most founders expect. A 2023 framework for selecting patient-facing software in a digital-first health system reports that healthcare breaches from 2005 to 2019 affected 249 million individuals. It places responsibility for security compliance on each enterprise system, including multifactor authentication, secure data access and transfer, and HIPAA compliance. Its implementation checklist covers business associate agreements (BAAs, the contracts HIPAA requires when a vendor handles patient data), privacy, risk and legal review, IT security review, data retention agreements, service-level agreements, uptime requirements, support responsibilities and downtime procedures.
In the same 2025 framework study, developers named HITRUST, SOC 2 Type II and HIPAA as reference standards that should be in place. The AMA's vendor selection guide lists the same family of checks: HIPAA and HITECH compliance, third-party audits such as SOC 2 and HITRUST, penetration testing, liability structure, authentication and transparency about data use.
A solid security evaluation therefore asks:
- Is there a documented, current HIPAA risk assessment? See our seven steps to a defensible HIPAA risk assessment.
- Which third-party attestation is in place or planned? Our comparison of HITRUST and SOC 2 for healthcare SaaS helps with that choice.
- Is any dataset de-identified by a method that would survive an audit? See HIPAA de-identification methods.
- Is a BAA signed before any patient data enters a shared space? Our note on healthtech data rooms and BAAs explains why this matters in diligence.
Engineering practices matter as much as paperwork. This walkthrough of HIPAA compliant development steps is useful when you want to check that the build process itself supports the controls you are claiming.
Implementation readiness and commercial viability
A product that passes clinical and security review still has to be deployed, paid for and maintained. The AMA's vendor guide organizes the buyer's view into business, IT, data security and privacy, usability and efficacy. Business covers cost, business model, ROI, reimbursement rates and financial viability. Efficacy covers prior results, peer-reviewed clinical evidence and the ability to meet the organization's own KPIs.
The 2023 enterprise framework adds the capabilities a health system expects: human-centered design, operational workflow, clinical content management, communication channels, reporting and analytics, standards-based integration, security and data management, and scalability.
Implementation research from large health systems identifies five issues that need resources: training, IT integration, information security, human capital investment, and adapting real-world and EHR workflows. It also notes that vendor machine-learning tools may need local training data to tune before deployment, and that data sharing requires a data-use agreement that specifies patient-data protection and permitted secondary use.
Turn that into a readiness scorecard:
| Question | Strong signal | Warning sign |
|---|---|---|
| Who pays and why? | Named budget holder, defined ROI metric | "Everyone benefits" with no buyer |
| What does go-live need? | Documented integration and training plan | Custom work for every site |
| Can support scale? | Defined SLAs, uptime and downtime procedures | Founders handling every ticket |
| What is the reimbursement path? | Clear pathway or a value case that stands without it | Revenue depends on an unproven code |
For a fuller founder-side view, see our health IT vendor assessment readiness checklist.
Evaluating AI-enabled products
AI changes the evaluation because the product can change, and because its quality depends on data most outsiders never see. The ICER-PHTI framework flags that algorithm quality and accuracy depend heavily on training-dataset details and model parameters that are difficult for outside entities to assess. It also requires user experience to be measured among a diverse set of end users who reflect the anticipated real-world population.
FDA's January 7, 2025 draft guidance on AI-enabled device software shows what regulators look for. According to a legal analysis of the draft, it recommends submission information on device description, user interface and labeling, risk assessment, data management, model development, validation, performance monitoring and cybersecurity. It stresses independent training and testing datasets, subgroup analyses, human-factors testing, transparency and post-market monitoring as a possible risk control. A trade-press summary adds that submissions should describe inputs and outputs, intended users and their training, the use environment, the intended workflow, and calibration and configuration tasks needed to maintain performance.
The draft guidance is aimed at devices under FDA review, but its logic is a good template for any AI product evaluation. Ask:
- Were training and test data kept separate, and were they independent of each other?
- How does performance vary by age, sex, race, site and condition?
- Where does the output land in the clinician's workflow, and what happens when the model is wrong?
- Who monitors performance after launch, and what triggers a retrain or a rollback?
- Does the product fall under FDA's device definition, or within the exemption for certain clinical decision support software? The legal analysis above explains how the agency's 2022 guidance reads the four statutory criteria for that exemption.
Regulatory positions on AI keep moving. FDA has described cross-agency work on methods for evaluating AI algorithms, including bias mitigation. Check FDA's own digital health pages for the status of any guidance before you rely on it for a filing.
From findings to decisions
An evaluation is only useful if it changes what happens next. Whether you are a founder or an investor, sort findings into three buckets.
Deal or launch blockers. Gaps that would end a procurement conversation: no BAA practice, no security attestation, evidence that does not match the risk tier, or an AI model with no monitoring plan.
Value drivers. Items that raise price or speed adoption: external validation, strong usability scores, clean EHR integration, a clear ROI metric.
Known unknowns. Questions with no answer yet. Put an owner and a study or test against each.
Structured frameworks help here. The ELICIT framework spans four IT life-cycle phases and three measure levels, society, user and IT, with 12 evaluation steps from business case assessment through implementation and long-term user satisfaction. The authors of the 2025 framework study argue that existing frameworks are fragmented and may miss what stakeholders care about most, and that harmonizing best practices across domains of trust and value eases adoption of trustworthy products.
For investors, the same findings feed diligence. Our guide to healthcare SaaS due diligence best practices shows how product evaluation sits beside financial and legal review. For founders, the output is a prioritized roadmap and a story a hospital buyer will believe.
Where a physician-led evaluation fits
The StartUp MD provides advisory services and fractional Chief Medical Officer leadership for healthcare SaaS companies. Our offering includes product evaluation, clinical strategy, regulatory guidance, market readiness assessment and investor support. Engagements run as advisory projects or as retainer-based fractional executive roles. Paul Bergeron, MD, MBA, brings more than 25 years of experience across medicine and business to that work.

If you are preparing a product for health system buyers, or reviewing one in a portfolio, you can see how we work on our services page.
Our perspective
Most product reviews I see are built from the engineering side or the sales side. The questions a health system actually asks come from the clinical side: Will this change a decision at the bedside? Will my physicians trust it? What happens when it is wrong?
That is why we treat evaluation as a clinical and commercial exercise together. A product can have clean code and a good deck and still stall because no clinician champion believes the evidence. Another can have modest technology and win because it removes a real burden from a real workflow.
Our approach rests on direct access to an advisor with both clinical and business expertise, and on practical medical leadership grounded in real patient care and startup growth. For founders, that means a fractional Chief Medical Officer who can shape evidence, usability and go-to-market strategy in the same conversation. For investors, it means a physician's read on whether the product, and the claims behind it, will hold up in the market you are betting on.
The gap a fractional Chief Medical Officer is built to close is the one between a promising product and a product a clinician will stake a patient's care on. If something in your evaluation feels misaligned, I would welcome a conversation.
Paul Bergeron MD, MBA
FAQ
What is the difference between a healthtech product evaluation and a health technology assessment?
A health technology assessment is a formal, multidisciplinary process, often run for payers or public bodies, that weighs effectiveness, safety, cost and wider impacts across a technology's life cycle. A product evaluation applies that thinking to a company's own decisions, such as readiness for a pilot or an investment. It adds operational and commercial questions, including integration, support and pricing.
How much clinical evidence does a digital health product need?
It depends on risk. Lower-risk diagnostic software typically needs accuracy and precision against a reference standard, ideally with external validation. Software that guides high-risk decisions may need a randomized trial showing better patient outcomes. Match the plan to the claims you make and the buyers you are targeting.
What should an evaluation of an AI healthcare product add?
Examine training and test data independence, performance across subgroups, human-factors testing and where the output sits in the clinical workflow. Add a post-launch monitoring plan with clear triggers for review. FDA's January 2025 draft guidance on AI-enabled devices is a useful reference for these elements.
Who should lead the evaluation inside a startup?
Someone with clinical credibility and commercial judgment. Many early-stage companies lack a full-time Chief Medical Officer, so they bring in a fractional one to lead evidence strategy, usability and buyer readiness. At The StartUp MD, that is a core part of our fractional Chief Medical Officer and advisory services.
Sources
- Frameworks for assessing digital health technologies: a scoping review (PMC, 2026)
- A European framework for the assessment of digital health technologies (PMC, 2026)
- ICER and Peterson Health Technology Institute framework (PMC, 2023)
- Development of an evidence-based evaluation framework for digital health software (PMC, 2025)
- ICER-PHTI Assessment Framework for Digital Health Technologies, ICER (2023)
- ICER-PHTI Assessment Framework for Digital Health Technologies, PHTI (2023)
- IMDRF, Software as a Medical Device: Clinical Evaluation (2017)
- From an idea to the marketplace: identifying and addressing barriers to digital health tools (PMC, 2024)
- Digital Health at Enterprise Scale, JMIR Formative Research (2023)
- Deploying digital health tools within large, complex health systems (PMC, 2022)
- AMA, Selecting a Vendor Guide (2018)
- Ropes & Gray, The Biden Administration's Swan Song on Digital Health (2025)
- MDDI, Navigating FDA's Draft Guidance for AI-Enabled Medical Devices (2025)
- Endpoints News, FDA lays out cross-agency efforts on regulating AI in medical products (2024)
- Evaluation in Life Cycle of Information Technology (ELICIT) framework (PMC, 2022)
